Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
Harrow (Nasdaq: HROW) will report fourth quarter and year-end 2025 financial results on March 2, 2026 after market close and will post a Q4 Letter to Stockholders on its Investors webpage.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Harrow (Nasdaq: HROW) will report fourth quarter and year-end 2025 financial results on March 2, 2026 after market close and will post a Q4 Letter to Stockholders on its Investors webpage.
The company will host a conference call and live webcast at 8:00 a.m. ET on March 3, 2026, with a replay available on the website for one year.
Details
News Market Reaction – HROW
On Feb 18, the day this news came out, HROW closed 1.33% below the previous close.
Data tracked by StockTitan Argus for the Feb 18 session.
Key Figures
- Earnings date
- March 2, 2026
- Q4 and full-year 2025 results after market close
- Conference call time
- 8:00 a.m. Eastern Time
- Results call on March 3, 2026
- Conference call date
- March 3, 2026
- Business update and Q4/FY 2025 discussion
- Webcast replay duration
- 1 year
- Replay availability on company website
Historical Context
-
Confirmed OSRX licensing and operations after a competitor exited California.
-
Reaffirmed 2025 revenue guidance and detailed commercial expansion initiatives.
-
Announced participation in two December 2025 investor conferences.
-
Closed acquisition of Melt Pharmaceuticals, adding MELT pipeline assets.
-
Reported strong Q3 2025 revenue growth and positive adjusted EBITDA.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 3, 2026
NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2025, on Monday, March 2, 2026, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, March 3, 2026, to discuss the results and provide a business update.
Conference Call Information
Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.
To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.
Contact:
Mike Biega
VP of Investor Relations & Communications
mbiega@harrowinc.com
617-913-8890
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.